Global Valsartan Drug Market Size By Type (40 mg Tablets, 80 mg Tablets), By Application (Hypertension, Heart Failure), By Region, And Segment Forecasts, 2023 to 2032

The Global Valsartan Drug Market was valued at USD 2.1 billion in 2023 and is projected to reach USD 3.4 billion by 2031, growing at a CAGR of 6.1% during the forecast period of 2023–2031. Valsartan, an angiotensin II receptor blocker (ARB), is widely used to treat high blood pressure, heart failure, and post-myocardial infarction complications. The market is witnessing steady growth due to the rising prevalence of hypertension and cardiovascular diseases worldwide. Additionally, the expiration of patents and increasing availability of generic valsartan formulations are contributing to market expansion, especially in developing regions.

Drivers:

1. Rising Prevalence of Cardiovascular Diseases:

The global burden of cardiovascular conditions, including hypertension and heart failure, is steadily increasing due to aging populations, sedentary lifestyles, and poor dietary habits. Valsartan plays a key role in managing these conditions, which significantly boosts its demand.

2. Increase in Generic Drug Penetration:

Following patent expirations, generic versions of valsartan have entered the market, improving affordability and accessibility. This is particularly beneficial in low- and middle-income countries, fueling global market growth.

3. Expanding Geriatric Population:

Older adults are at higher risk of cardiovascular issues. The aging global population is expected to drive sustained demand for antihypertensive drugs like valsartan over the forecast period.

Restraints:

1. Product Recalls Due to Impurities:

Several global recalls of valsartan formulations have occurred due to the detection of nitrosamine impurities. These recalls have led to reduced consumer trust and increased regulatory scrutiny.

2. Competition from Other ARBs and Antihypertensives:

While valsartan is a leading ARB, it faces strong competition from other ARBs like losartan and olmesartan, as well as from ACE inhibitors and calcium channel blockers, potentially limiting its market share.

Opportunity:

1. Growth in Emerging Markets:

Emerging economies such as India, Brazil, and Southeast Asian countries offer robust growth opportunities due to improving healthcare access, rising hypertension awareness, and increased generic drug manufacturing capacity.

2. Combination Therapy Development:

The development of fixed-dose combination drugs that include valsartan with other antihypertensives (e.g., hydrochlorothiazide, amlodipine) is gaining traction. These formulations enhance treatment efficacy and patient compliance.

Market by System Type Insights:

Based on drug formulation type, oral tablets represent the largest market share due to their convenience, cost-effectiveness, and widespread adoption. Among these, generic valsartan tablets dominate the volume sales, driven by lower pricing and government support for generics. However, combination tablets, particularly those paired with amlodipine or hydrochlorothiazide, are expected to witness the fastest growth owing to their synergistic effects and growing demand for simplified dosing regimens.

Market by End-use Insights:

By end-use, the hospital pharmacies segment holds the largest share, attributed to high prescription volumes and the critical role of valsartan in inpatient cardiovascular care. Retail pharmacies follow, driven by the chronic nature of hypertension requiring ongoing outpatient prescriptions. The online pharmacy segment is emerging rapidly, bolstered by digital health trends and rising telemedicine adoption.

Market by Regional Insights:

Geographically, North America led the global valsartan drug market in 2023, owing to its high prevalence of cardiovascular diseases, strong healthcare infrastructure, and widespread insurance coverage. However, Asia-Pacific is poised to grow at the fastest rate during the forecast period, propelled by large hypertensive populations, government initiatives for affordable generics, and improved healthcare accessibility in countries like India and China. Europe also remains a significant market due to its aging population and regulatory support for generic drug adoption.

Competitive Scenario:

Key players operating in the global valsartan drug market include Novartis AG, Mylan N.V. (now part of Viatris Inc.), Teva Pharmaceutical Industries Ltd., Zydus Lifesciences, Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals, Lupin Limited, and Aurobindo Pharma Ltd. These companies are focused on producing high-quality generics, ensuring regulatory compliance, and expanding their reach through strategic partnerships and distribution networks.

Recent Developments:

2023: Viatris expanded its valsartan portfolio with combination therapies targeting multi-pathway hypertension management.

2024: Zydus Lifesciences received US FDA approval for a new generic valsartan-hydrochlorothiazide formulation.

2025: Lupin partnered with a regional distributor in Southeast Asia to boost valsartan product accessibility.

Scope of Work – Global Valsartan Drug Market

FAQs:

1) What is the current market size of the Global Valsartan Drug Market?

The Global Valsartan Drug Market was valued at USD 2.1 billion in 2023.

2) What is the major growth driver of the Global Valsartan Drug Market?

The major growth driver is the rising prevalence of hypertension and cardiovascular diseases globally.

3) Which is the largest region during the forecast period in the Global Valsartan Drug Market?

North America held the largest market share in 2023, though Asia-Pacific is expected to grow fastest.

4) Which segment accounted for the largest market share in the Global Valsartan Drug Market?

The oral tablets segment, particularly generic formulations, accounted for the largest market share.

5) Who are the key market players in the Global Valsartan Drug Market?

Key players include Novartis AG, Viatris Inc., Teva, Zydus, Sun Pharma, Torrent Pharma, Lupin, and Aurobindo Pharma.